ViiV Sees Cabenuva In Adolescents Addressing Adherence, Psychological Distress

Reducing the frequency of dosing to six times a year instead of daily pills could help reduce some of the psychological trauma teens with HIV face, chief medical officer Harmony Garges told Scrip.

ViiV announced the approval of Cabenuva in adolescents • Source: Alamy

Despite addressing a small market, the US Food and Drug Administration approval of ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) in adolescents could make a big difference in terms of uptake and adherence of HIV therapy in that age group, the company believes, as well as helping to address some of the lingering stigma around HIV and related psychological issues that adolescent patients face.

The FDA approved Cabenuva on 29 March for adolescents living with HIV who are 12 and older and weigh at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

More from Scrip

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.